Skip to content

The Clinical Effects of Laser Acupuncture Therapy for OAB Women.

The Clinical Effects of Laser Acupuncture Therapy for OAB Women: a Randomized Controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03829137
Enrollment
30
Registered
2019-02-04
Start date
2019-01-01
Completion date
2022-04-05
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Brief summary

Overactive bladder (OAB) is a syndrome causes urgency, with or without urgent incontinence, daytime frequency and nocturia. Urgency incontinence is more common in older women and may be associated with comorbid conditions that occur with age. The standard OAB medical treatments may induced several intolerable side effects including dry mouth, constipation, and so on, therefore alternative therapies are often considered. Acupuncture had been proved effective to OAB treatment, however, this invasive procedure also cause pain and hematoma. Laser acupuncture has minimal side effects comparing to conventional acupuncture, but its effects against OAB had never been examined. Experiments with laser acupuncture are expected to be another way to relieve OAB symptoms.

Detailed description

The subjects are treated with 7 acupoints which are localized according to WHO standardized acupressure point location guideline. The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints mentioned above. The experimental group (verum laser acupuncture) and control group (sham laser acupuncture) will receive laser acupuncture 3 times per week for 3 weeks, total of 9 sessions, based on clinical experience (Treatment could be extended if necessary). The basic patient data will be recorded at baseline and adverse effect will also be recorded during the clinical trial.

Interventions

The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.

DEVICESham laser acupuncture

The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Women are older than 18 years old. 2. Participant is willing to sign the consent. 3. Women havea moderate OAB symptoms. 4. Total scores of OABSS \> 6 points and the 3rd question of OABSS \> 2 points. 5. Not using anticholinergic drugs for more than three weeks.

Exclusion criteria

1. Patients with lower urinary tract infection. 2. Patients who cannot complete the questionnaire. 3. Patients who use Botox to inject bladder and pelvic floor muscles within one year. 4. Pregnant patients. 5. Patients who continue to have electrical stimulation and acupuncture in the legs, waist and pelvis. 6. Patients with vaginal bleeding. 7. Other herbal and folklore therapies are being used to improve patients with overactive bladder.

Design outcomes

Primary

MeasureTime frameDescription
OAB symptom score (OABSS)3 weeksThis is a four symptoms questionnaire to quantify OAB symptoms.

Secondary

MeasureTime frameDescription
The Urogenital Distress Inventory (UDI-6)3 weeksThis evaluation scale assesses symptom distress.

Other

MeasureTime frameDescription
Incontinence Impact Questionnaire (IIQ-7)3 weeksThis evaluation scale assesses the impact on daily life of urinary incontinence.

Countries

Taiwan

Contacts

Primary ContactHsin-Ning Chang
8705015@cgmh.org.tw(02)24313131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026